Supply channels are becoming more and more complex, and their models are evolving with an abundance of services to support both the providers and suppliers. Such complexity is causing both challenges and opportunities in this arena. What does the future hold?
Read More
Read More
Clinical trials have evolved over the years from gated phase 1, 2, and 3 approaches to more blended phase options and single-arm trials. However, we’re still seeing many of the same challenges, such as lack of patient access and diversity, similar or rising cost, and increasing complexity. Our panel of experts discussed the evolution of clinical trials and some unique solutions being considered for the future.
Read More
Read More
From the Pharmacy Benefits Manager (PBM) Reform Act and 340B Drug Pricing Program to drug shortages and the Inflation Reduction Act, this panel of Washington healthcare experts separated fact from fiction and noise from reality to provide a clear understanding for current legislative priorities.
Read More
Read More
Cancer treatments are advancing rapidly, thanks to the diligence of researchers and the foundations that support them. Panelists discussed emerging therapies, the impact of funding organizations, and what the future holds for the fight against cancers.
Read More
Read More
Artificial intelligence (AI) and machine learning (ML) platforms are becoming essential to the value equation in healthcare and to managing the complexity and range of treatment options within cancer care today. Panelists in this session explored the application of AI and ML technologies and their impact on care, outcomes, cost, providers, pharma, payers, and patients as well as their integrations between electronic medical records and future systems.
Read More
Read More
On August 16, 2022, President Biden signed the Inflation Reduction Act into law, marking the first time the US Government will place direct price controls on many drugs covered by Medicare. The Medicare Part D benefit will also be restructured, and an annual patient out-of-pocket cap will be introduced.
Read More
Read More
By Wayne Kuznar
At the 12th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2022, held October 19-21, 2022, in New York City, a panel of experts from Upstream Partners discussed the current state of value-based agreements (VBAs) in pharma and what lies ahead. The session was moderated by Burt Zweigenhaft, PhD, DLitt, Executive Director and Co-Founder of AVBCC.
Read More
Read More
The 12th Annual Summit of the Association of Value-Based Cancer Care (AVBCC) in 2022 was the site of an encouraging and positive trend that is taking on more prominence in US healthcare: recognition, discussion of, and intervention around social determinants of health (SDoH). Although the concept that SDoH has an identifiable and actionable influence on health is not new, there are clear signs that thinking is moving more broadly beyond something we are considering to something we can actually use to improve healthcare.
Read More
Read More
The traditional role of oncology physicians as providers who diagnose disease and provide treatment has evolved as healthcare has shifted from a purely clinical discipline to one where patient-centered care is the focus.
Read More
Read More
Although The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved was published in 1999 and Z-codes were added to the International Classification of Diseases codes in 2015, social determinants of health were barely considered prior to the COVID-19 pandemic.
Read More
Read More